



Biotech Daily

Tuesday May 1, 2012

Daily news on ASX-listed biotechnology companies

- * **APRIL BDI-40 FLAT, ASX200 UP 1.4%**
- HEARTWARE, SIRTIX, CELLMID, PSIVIDA UP; SUNSHINE HEART DOWN
- * **TODAY: ASX UP, BIOTECH DOWN: PRANA UP 10%, LIVING CELL DOWN 12%**
- * **ADAPTIVE SONICS FILES PATENT INFRINGEMENT AGAINST COCHLEAR**
- * **ATCOR LAUNCHES SPHYGMOCOR XCEL SYSTEM**
- * **US COURT ALLOWS MAYNE PHARMA DORYX GENERICS**
- * **LIVING CELL SHARE PLAN RAISES \$1m**
- * **IDT PROFIT WARNING**
- * **EX-CHAIRMAN THEODORE ONISFOROU REDUCES TO 5% OF CRYOSITE**
- * **IMPEDIMED REQUESTS CAPITAL RAISING TRADING HALT**
- * **PHARMAUST HAS ONE QUARTER CASH**
- * **CONSEGNA HAS ONE QUARTER CASH, LINGUET SALE TRADING HALT**
- * **IMUGENE REQUESTS ACQUISITION TRADING HALT**
- * **MALCOLM MCCOMAS REPLACES PHARMAXIS CHAIRMAN DENIS HANLEY**
- * **BRUCE PARNCUTT REPLACES ACRUX DIRECTOR KEN WINDLE**

MARKET REPORT

The Australian stock market was up 0.75 percent on Tuesday May 1, 2012 with the S&P ASX 200 up 32.9 points to 4,429.5 points. Eight of the Biotech Daily Top 40 stocks were up, 12 fell, 15 traded unchanged and five were untraded.

Prana was the best, up 1.5 cents or 10.3 percent to 16 cents with 214,759 shares traded. Tissue Therapies climbed 5.4 percent; Allied Health and Nanosonics were up more than three percent; Phosphagenics rose 2.3 percent; with Acrux, Biota and CSL up more than one percent.

Living Cell led the falls, down 0.9 cents or 12.2 percent to 6.5 cents with 138,082 shares traded followed by Neuren down 6.9 percent to 2.7 cents, with 15.1 million shares traded. Sunshine Heart lost 3.45 percent; Clinuvel, Genera, Pharmaxis and Prima shed more than two percent; with Cochlear, QRX, Reva and Starpharma down more than one percent.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

The Biotech Daily Top 40 Index (BDI-40) barely changed in April, down 0.07 percent to a market capitalization of \$7,556 million, compared to the S&P ASX200 up 1.4 percent.

For the year to April 30, the BDI-40 (which does not include the Big Caps of Cochlear, CSL and Resmed) was down 7.8 percent from its all-time high of \$8,197 million, compared to the ASX200 falling 8.8 percent for the year and 34.9 percent below its all-time high at October 30, 2007.

Since June 30, 2006, the BDI-40 has climbed 112 percent, while the ASX 200 has fallen 13.3 percent.


The Big Caps were up 3.2 percent for the month, with CSL up 0.6 percent to \$18,861 million, Cochlear up 8.1 percent to \$3,737 million and Resmed up 10.1 percent to \$5,089 million. The Big Caps were down just 0.5 percent over the 12 months to April 30.

Fourteen of the BDI-40 stocks were up, 19 fell and seven were untraded. The BDI-20 was up \$49 million, primarily Heartware's \$169 million or 19.0 percent jump on a favorable FDA Panel vote (BD: Apr 26, 2012), while the Second 20 fell \$54 million with Phosphagenics \$25 million fall the single largest.


Cellmid was technically the best up 33.3 percent from a low base to \$8 million, followed by last month's best, Psivida, up a further 25 percent to \$50 million; but the 23.6 percent improvement by Sirtex was more significant, up \$69 million to \$361 million, followed by Genera Biosystems (23.1%), Heartware (19.0%), Neuren (17.2%), Benitec (11.8%) and Phylogica (10.0%).

Sunshine Heart led the falls for the second month in a row, down \$8 million or 18.6 percent to \$35 million, followed by Bioniche down 17.4 percent to \$57 million, Avita (15.8%), Biota (14.4%), Bionomics (13.0%), Optiscan (11.1%), Impedimed (10.7%), Antisense (10.5%), Prima (10.5%), Prana (10.4%) and Viralytics (10.3%).

BDI-40 v ASX200 Jun 30, 2006 To Apr 30, 2012



BDI-40 v ASX200 Apr 30, 2011 To Apr 30, 2012



COCHLEAR

Cochlear says that Adaptive Sonics LLC has filed a complaint for patent infringement in the US District Court, Eastern District of Texas in Dallas.

Cochlear said that the complaint named it and its US subsidiary Cochlear Americas Corp as defendants for infringing US Patent 5,473,701 entitled 'Adaptive Microphone Array' filed on November 3, 1993.

The company said the allegations of infringement were without merit and it intended "to vigorously defend against the complaint".

Cochlear said the complaint had been filed but not served on either it or its US subsidiary. Cochlear fell 82 cents or 1.25 percent to \$64.83 with 191,031 shares traded.

ATCOR MEDICAL

Atcor says it has launched the Sphygmocor Xcel system at the European Society of Hypertension Congress in London.

Atcor said the Sphygmocor Xcel system automated and improved data capture for its non-invasive technology for measuring central blood pressure, making the system easier to use for clinicians.

The company said that the Xcel system included simultaneous brachial and central aortic blood pressure measurement, as well as "carotid-femoral pulse wave velocity" using inflatable cuffs while the patient was fully clothed, helping to simplify the procedure for medical professionals.

Atcor said the new product had received Conformité Européenne (CE) mark certification for European sales and distribution and was cleared for sale in Australia.

The company said that sales in Europe, Australia and select Asian markets would begin today with US sales expected to begin later in 2012.

Atcor's chief executive officer Duncan Ross said the new generation Sphygmocor was intended to preserve data quality in a system that was easy to use.

"The Sphygmocor Xcel system shows our success as it can measure brachial and central aortic blood pressure in 60 seconds," Mr Ross said.

Atcor said it had filed patent applications covering the signal processing and wave form analysis technologies used in the Sphygmocor Xcel.

Atcor was untraded at 7.9 cents.

MAYNE PHARMA GROUP

Mayne Pharma says the US District Court has upheld its US patent covering Doryx 150mg product but said proposed generic versions did not infringe the patent.

Mayne Pharma said the New Jersey District Court upheld the validity of the patent, but determined that neither Mylan Pharmaceuticals nor Impax Pharmaceuticals proposed generic versions of Doryx 150mg infringed the patent (BD: Sep 22, 2011; Feb 10, 2012). Mayne said that its US marketing and distribution partner Warner Chilcott was reviewing the Court's decision and intended to appeal the non-infringement determinations and Mayne would support Warner Chilcott in any such action.

The company said that it believed Mylan had entered the market with its US Food and Drug Administration-approved Doryx 150mg generic tablets, but it was unclear how much stock Mylan had manufactured and, with the uncertain rate of generic substitution, the financial impact was uncertain.

Mayne Pharma said it was "confident" with the prospects for its non-Doryx products and the provision of contract manufacturing services.

The company said it would maintain a positive underlying result and could continue to invest in new business opportunities, irrespective of the ongoing level of US Doryx sales. Mayne Pharma chief executive officer Scott Richards said that although the company was disappointed by the decision, "we have prepared the business for such an outcome". Mayne was up two cents or 6.9 percent to 31 cents.

LIVING CELL TECHNOLOGIES

Living Cell says that its share purchase plan has raised more than \$1 million and shares will be issued at 6.05 cents each.

Living Cell had hoped to raise \$3 million (BD: Mar 20, 2012).

Living Cell fell 0.9 cents or 12.2 percent to 6.5 cents.

IDT

IDT says its net loss after tax for the year to June 30, 2012 is expected to be more than the first six months loss of \$773,000.

IDT said that it had a number of fee-for-service projects with projected revenues of about \$800,000 delayed until the 2012-'13 financial year.

IDT fell 2.5 cents or 8.5 percent to 27 cents.

CRYOSITE

Former chairman Theodore Onisforou has reduced his substantial holding in Cryosite from 4,115,004 shares (8.82%) to 2,508,753 shares (5.38%).

In the change of substantial shareholder notice, Mr Onisforou said that with Sentra Investments, he last bought 10,000 shares in 2010 and between April 26 and 30, 2012 sold 1,616,251 shares on-market for \$250,852 or an average price of 15.5 cents a share. Cryosite was untraded at 16 cents.

IMPEDIMED

Impedimed has requested a trading halt pending an announcement in relation to a proposed capital raising and will resume on May 3, 2012 or an earlier announcement. Impedimed last traded at 43 cents.

PHARMAUST

Pharmaust says its net operating cash burn for the three months to March 31, 2012 was \$84,000 with cash at the end of the quarter of \$104,000.

Pharmaust director Sam Wright told Biotech Daily there would be "further clarification in announcements to come".

Pharmaust was untraded at 1.2 cents.

CONSEGNA GROUP

Consegna says its net operating cash burn for the three months to March 31, 2012 was \$1,411,000 with cash at the end of the quarter of \$1,455,000.

Consegna managing director Fabio Panutti told Biotech Daily that with the sale of the Linguet intellectual property (see below) there other transactions were being considered.

Separately, Consegna requested a trading halt pending an announcement in relation to the proposed sale of the Linguet intellectual property, having acquired all the rights to Linguet by issuing 25,000,000 shares to the original owner Ozpharma (BD: Apr 27, 2012). Trading will resume on May 3, 2012 or on an earlier announcement.

Consegna last traded at 3.3 cents.

IMUGENE

Imugene has requested a trading halt pending "the outcome of a negotiation for the acquisition of a business opportunity.

Last year, Novartis terminating its licence agreement for development and commercialization of Imugene's vaccines for pigs and poultry (BD: Sep 2, 2011).

Trading will resume on May 3, 2012 or on an earlier announcement.

Imugene last traded at 0.9 cents.

PHARMAXIS

Pharmaxis says that chairman Denis Hanley has retired from the board and director Malcolm McComas has been appointed chairman, effective immediately.

Pharmaxis said that Mr Hanley has been chairman since 2001, overseeing the building of the company and its successful clinical research and development program.

The company said Mr McComas had been a director since July 2003 and was previously a director and a consultant to investment group Grant Samuel, from 1999 to 2009.

Pharmaxis said Mr McComas was previously County Natwest's managing director of investment banking and was currently a director of BC Iron and Ocean Capital.

Pharmaxis fell three cents or 2.3 percent to \$1.30.

ACRUX

Acrux says Bruce Parncutt will replace non-executive director Ken Windle who has retired after more than 10 years on the board.

Acrux said that Mr Parncutt had about in investment management, investment banking and stockbroking including seven years as chief executive of listed securities firm McIntosh Securities and three years as Merrill Lynch senior vice-president.

The company said that Mr Parncutt had experience in financial analysis, merger and acquisition transactions, capital-raising and investment.

Acrux was up four cents or one percent to \$4.05 with 1.5 million shares traded.

BIOTECH DAILY'S TOP 40 WITH MARKET CAPITALIZATION

Company \$Am	May-11	Apr-12	May-12
Cochlear	4,569	3,458	3,737
CSL	18,458	18,753	18,861
Resmed	4,527	4,622	5,089
BDI-20			
Acrux	581	664	668
Alchemia	131	145	146
Bionomics	185	169	147
Biota	217	181	155
Clinuvel	58	57	56
Genetic Technologies	63	44	44
Heartware	950	890	1,059
Impedimed	109	75	67
Living Cell	37	27	25
Mesoblast	2,280	2,264	2,134
Nanosonics	204	130	118
Pharmaxis	682	416	407
Phylogica	21	20	22
Prima	283	256	229
QRX Pharma	245	251	263
Sirtex	297	292	361
Starpharma	312	491	520
Sunshine Heart	53	43	35
Tissue Therapies	77	74	79
Universal Biosensors	223	116	119
Second 20			
Allied Health	6	22	21
Anteo	53	62	62
Antisense	10	19	17
Avita	17	57	48
Benitec	12	17	19
Bioniche	138	69	57
Cellmid	11	6	8
Circadian	33	23	23
Compumedics	18	12	12
Ellex	15	16	16
Genera	18	13	16
Neuren	7	29	34
Optiscan	7	18	16
Patrys	37	12	12
Phosphagenics	119	244	219
Prana	59	48	43
Psivida	83	40	50
Reva	396	215	198
Uscom	13	5	5
Viralytics	31	29	26

* Biotech Daily editor, David Langsam, owns shares in Alchemia, Allied Health, Biota, Neuren, Pharmaxis and non-biotechnology stocks. Through Australian Ethical Superannuation he has an indirect interest in Atcor, Avita, Circadian, Pharmaxis and QRX. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: @biotech_daily